Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Bringing Down the House on Intellectual Property and Access

As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American ingenuity,” this issue of TAGline dives deep into the rhetoric and realities of intellectual property (IP) protections and the current wave of political shenanigans on critical drugs, surfacing the fundamental lies and vested interests that deny medication to those in need in the United States and around the world.

Published
10 December 2018
From
Treatment Action Group
Roche Executive Daniel O’Day Is Named Gilead CEO

The industry veteran will be tasked with helping the drug company revive sales, recover from a disappointing deal

Published
10 December 2018
From
Wall Street Journal
Pharmaceutical corporations are failing children with HIV

One year ago, pharmaceutical corporations committed to improving access to paediatric versions of HIV drugs for children, but very little progress has been made. MSF urges pharmaceutical corporations including Viiv and Merck to immediately register paediatric ARVs and improve access for kids.

Published
30 November 2018
From
Médecins Sans Frontières (MSF)
Trump Wants to Restrict Access to HIV Meds for People on Medicare

In a move to cut Medicare costs, the proposed changes would also affect people with cancer, depression and schizophrenia.

Published
29 November 2018
From
Poz
MSF: Pharmaceutical corporations failing children with HIV

Developing countries are struggling to provide HIV-positive children with World Health Organization (WHO)-recommended treatments because pediatric versions of HIV medicines don’t exist, are priced out of reach, or haven’t been registered in all countries that need them, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ahead of a Vatican City meeting of HIV stakeholders on scaling up diagnosis and treatment for children.

Published
29 November 2018
From
Doctors Without Borders
Gilead investors spooked by UnitedHealthcare push to cut HIV drug costs

Unveiled this week, UnitedHealthcare’s MyScriptRewards program will offer patients up to $500 in prepaid debit cards for medical expenses if they work with their doctors to choose lower-cost HIV drug regimens. The program is rolling out in HIV antivirals to start, with other specialty drug classes to follow.

Published
05 November 2018
From
FiercePharma
Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?

Gilead has been under pressure over the last year to prove that its new products to treat HIV and cancer will perform well enough to counteract a faster-than-expected decline of its hepatitis C franchise. The third quarter did produce a glimmer of hope—particularly in HIV—but as is often the case with Gilead, the good news was met with some skepticism about the company’s continued growth prospects.

Published
29 October 2018
From
FiercePharma
Patients 'may need to stockpile own drugs if no-deal Brexit looms'

Patients should consider stockpiling their own drugs if it looks likely the UK will leave the EU with no deal, the pharmaceuticals industry has said, telling MPs that such a scenario could be “catastrophic” for medicine supplies and necessitate emergency powers.

Published
23 October 2018
From
The Guardian
Johnson & Johnson prices keep key TB medicines out of reach

As US pharmaceutical corporation Johnson & Johnson (J&J) continues to charge high prices for its newer tuberculosis (TB) drug bedaquiline, people with drug-resistant tuberculosis (DR-TB) are forced to go without the best possible treatments, according to a new report—DR-TB Drugs Under the Microscope—released today by Doctors Without Borders/Médecins Sans Frontières (MSF) at the 49th Union World Conference on Lung Health in The Hague. J&J should cut the price of bedaquiline in half so more lives can be saved, said the international medical humanitarian organization MSF.

Published
23 October 2018
From
MSF
Gilead and Aelix join forces to pursue HIV 'cure'

Gilead Sciences – already a giant in HIV therapy – has teamed up with Spanish biotech Aelix Therapeutics to try to develop a treatment regimen that would go beyond controlling the virus and provide an effective cure for the infection.

Published
18 October 2018
From
PMLiVE
← First12345...108Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.